Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Kenneth R. Fromkin, MD, FACC, FSCAI, was born and raised in northern New Jersey. He has been with Cleveland Clinic Florida since 2001, initially as Assistant Director of the Cardiac Catheterization Laboratory, and since 2007, as Director of Invasive and Interventional Cardiology.
Dr. Fromkin performs all aspects of interventional cardiology including angioplasty, stenting, hemodynamic assessments, intravascular ultrasound, fractional flow reserve procedures, thrombectomy, rotational atherectomy, intra-aortic balloon pump, treatment of ACS, and primary PCI for acute MI. He specializes in complex catheter-based coronary artery interventions for difficult lesions, multivessel coronary artery disease, left main disease in nonsurgical patients, rotational atherectomy, degenerated bypass graft interventions, balloon pump-supported procedures and chronic total occlusions including advanced retrograde technique. He provides second opinions for complex coronary artery disease and for technically complex or difficult interventions. He also performs peripheral arterial interventions of the distal aorta, renal arteries, subclavian arteries, iliac arteries, femoral arteries, and of the arteries of the legs for the treatment of claudication and/or critical limb ischemia. He does not stent carotid arteries.
Dr. Fromkin is a 1990 graduate of The Johns Hopkins University, where he earned a BA in Biology. He graduated from The University of Chicago Pritzker School of Medicine in 1994, and completed a 3 year residency in Internal Medicine at Yale-New Haven Hospital in 1997. He then completed a 3 year Cardiovascular Disease fellowship at New York Presbyterian Hospital, Weill Cornell, in 2000 and then completed a second fellowship in Interventional cardiology, also at New York Presbyterian, Weill Cornell, in 2001. He has been with Cleveland Clinic Florida since completion of his second fellowship in 2001.
Dr. Fromkin is board-certified and recertified in both Cardiovascular Disease and in Interventional Cardiology. Dr. Fromkin's interests lie in the catheter-based techniques of coronary artery and peripheral artery angiography and intervention. In particular, he specializes in complex and difficult interventional cardiology and peripheral arterial angiography cases and welcomes second opinions in these areas.
Dr. Fromkin has been selected as a Castle Connolly regional Top Doctor in Interventional Cardiology from 2008-2011. He has also been selected as one of America's Top Cardiologists by Consumer's Research Council of America from 2007-2011.
Dr. Fromkin is also an instructor and mentor for cardiology fellows from Cleveland Clinic Florida's fully accredited cardiology fellowship in the cardiac catheterization laboratory and in inpatient and outpatient cardiology settings.
Coronary Artery Angiography, Left and Right Cardiac Catheterization, Invasive Hemodynamic Monitoring Procedures, Pulmonary Arterial Hypertension Reversibility Studies, Angioplasty, Stenting, Drug Eluting Stenting, IVUS, FFR, Intra-Aortic Balloon Pump Insertion, Rotational Atherectomy, Rheolytic Thrombectomy, Subclavian, Renal, Iliac, Femoral, and Upper and Lower Extremity Angiography and Endovascular Interventional Arterial Procedures.
Awards & Honors
Regional Castle Connolly Top Doctor, Interventional Cardiology, 2008-2011
America's Top Cardiologists, Consumer's Research Council of America, 2007-2011
Innovations & Patents
Dr. Fromkin has been involved in some of the original studies of the hybrid coronary artery revascularization strategy which combines an interventional cardiology approach with a minimally invasive surgical approach to address multivessel coronary artery disease. In this treatment strategy, PCI and stenting of non-LAD vessels is combined with single-vessel minimally invasive closed chest robotic bypass surgery to achieve complete coronary artery revascularization without the need for traditional open chest bypass surgery. This research was highlighted at the American College of Cardiology's 52nd Annual Scientific Session at a press conference showcasing the most noteworthy abstracts presented at that meeting. Many patients with multivessel coronary artery disease have been helped by this strategy of revascularization and have avoided sternotomy while still having all of their coronary artery lesions addressed.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 7/13/2012, Dr. Fromkin has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.